Parliament House hosts biotech policy forum

Biotech News: Canberra’s Parliament House hosted biotech leaders for strategic discussions and insightful presentations. The AusBiotech annual Policy Forum marked a significant collaboration between industry and government officials, underscoring the vital intersection of capital, policy and innovation shaping the evolving biotechnology landscape.

The 2023 CEO delegation, comprising Amplia Therapeutics, BioDiem, CSL, Esfam Biotech, Microbio, SpeeDx, Relix Pharmaceuticals, UniQuest, Vaxxas, and others, focussed on pivotal discussions revolving around the vitality of financial capital, deemed the ‘lifeblood’ nurturing the growth of the biotech sector. These discussions delved into capital attraction initiatives and opportunities outlined in the Biotechnology Blueprint.

In attendance were The Hon Ed Husic (MP), Minister for Industry and Science, along with notable representatives from the Department of Health and Aged Care, the Department of Industry, Science and Resources, and Treasury.

The AusBiotech CEO Policy Forum served as a pivotal platform for biotech leaders to gain insights into the government’s objectives. Simultaneously, it provided a unique opportunity for government officials to delve deeper into the impact of life sciences on the nation’s economy.

Central to the discussions were key policy areas that underpin the biotech sector’s progress, including the implications of quantum advancements on biotech, policy mechanisms to allure greater private investments, and the scope of government funding within the industry. A CEO workshop further fostered discussions on proactive policy initiatives aimed at supporting industry-driven medical research, effectively charting the trajectory for AusBiotech’s future policy endeavours and advocacy work.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.